. Saphner, Annual hazard rates of recurrence for breast cancer after primary therapy., Journal of Clinical Oncology, vol.14, issue.10, pp.2738-2746, 1996.
DOI : 10.1200/JCO.1996.14.10.2738

W. Ep, H. C. , and B. Hj, American society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for woman with hormone-receptor-positive breast cancer, status report, J Clin Oncol, vol.20, issue.15, pp.3317-3344, 2002.

D. Cremoux-p, Aromatase inhibitors: pharmacological aspects, Bull Cancer, vol.87, pp.23-32, 2000.

G. A. , I. Jn, and G. Rd, Thresholds for therapies: highlights of the St GallenInternational: the primary therapy of early breast cancer, Ann Oncol, vol.20, issue.8, pp.1319-1329, 2009.

C. Rc, H. E. , and G. Lj, A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer, N Engl J Med, vol.350, pp.1081-92, 2004.

G. Pe, I. Jn, and M. S. , A randomized trial of Letrozole in postmenopausal women after five years of Tamoxifen therapy for early-stage breast cancer, N Engl J Med, vol.349, pp.1793-802, 2003.

I. Jn, D. M. , C. J. , and D. C. , Aromatases Inhibitors versus Tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer :meta-analyses of randomized trials of monotherapyand switching strategies, Cancer Res, p.69, 2009.

A. A. Tas-f, Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer, Trials, vol.9, p.47, 2008.

G. Pa, G. Ga, and . Peterson-l, Breast Cancer in younger women: reproductive and late health effects of treatment, pp.4184-93, 2003.

P. Ai and I. L. Bowles-e-j-a, Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates, Maturitas, pp.67-60, 2010.

O. O. Pagani-o and J. A. , Which factors should be taken in account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor ? Recommandations of an expert panel, Cancer Treat Rev, p.1016, 2010.

L. Js, E. B. , and S. Fz, Comparison of methods to measure low serum estradiol levels in postmenopausal women, J Clin Endocrinol Metab, pp.913791-913798, 2006.

F. Van-disseldorp-j, T. Mj, and . Ap, Relationship of Serum Antim??llerian Hormone Concentration to Age at Menopause, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.6, pp.2129-2163, 2008.
DOI : 10.1210/jc.2007-2093

S. Mr, E. Ad, and C. Mc, Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition, J Clin Endocrinol Metab, pp.93-3478, 2008.

K. J. Schatsr and J. Mcdonnell, Evaluation of anti-mûllerian hormone as a test for the prediction of ovarian reserve, Fertil Steril, pp.90-737, 2008.

. Van-beek-rd, . Van-den-heuvel-eibrink, L. Mm, and . Js, Anti-Mullerian hormone is a sensitive serum marker fogonodal function in women treated for Hodgkin's lymphoma during childhood, J Clin Endocrinol Metab, pp.92-3869, 2007.

W. C. , L. Js, and V. Bergh-ar, Anti-mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment, Mol Human Reprod, pp.1077-83, 2004.

W. Ds, C. Ms, and M. Pj, Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women, J Clin Endocrinol Metab, pp.92-1871, 2007.

H. Wj, L. Cw, and T. Ap, Anti-mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation, J Clin Endocrinol Metab, pp.91-4057, 2006.

D. As and V. J. , Undetectable antimullerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor, Ménopause, pp.18-821, 2011.

A. Y. , G. Du-masgenet-b, and C. P. , Echographie et imagerie pelvienne en pratique gynécologique, 5 ème edition, p.193, 2010.

S. As, M. F. , and H. Lm, Transvaginal ultrasound measurement of endometrial thickness as a biomarker for estrogen exposure, Cancer Epidemiol Biomakers Prev, vol.13, pp.1459-65, 2004.

A. Y. , G. Du-masgenet-b, and C. P. , Echographie et imagerie pelvienne en pratique gynécologique, 5 ème edition, p.409, 2010.

B. Lf, B. Fj, and E. Mj, Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve, Fertil Steril, vol.77, pp.328-364, 2002.

S. Fi and S. Rt, Assessment of ovarian reserve.Is there still a role for ovarian biopsy ? First do not harm! Hum Reprod, pp.470-471, 2004.

B. Mc, Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women : a systematic review and meta-analysis, Ultrasound Obstet Gynecol, vol.40, pp.621-630, 2012.

F. Js and C. M. , Chimiothérapie des cancers du sein non métastatiques : état des lieux en 2010, J Gynecol Obstet Biol Reprod, vol.39, issue.8, pp.79-84

M. M. and V. A. Sole-calvo-a, Doxorubicin in combination with fluorouracil and cyclophosphamide as adjuvant chemotherapy for operable breast cancer: a study by the GEI-CAM group, Ann Oncol, vol.14, issue.6, pp.833-875, 2003.

S. Ja, W. M. , and M. S. , Weekly paclitaxel in the adjuvant treatment of breast cancer, N Engl J Med, issue.16, pp.358-1663, 2008.

T. Yl and W. H. Sexton-k, The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxanes, Am J Clin Oncol, vol.30, pp.126-158, 2007.

G. Pj, E. M. , and P. Ki, Risk of Menopause during the first year after breast cancer diagnosis, J clin Oncol, vol.17, issue.8, pp.2365-2370, 1999.

F. T. and B. Ma, Fertility preservation and pregnancy outcome after malignancy, Curr Opin Obstet Gynecol, vol.17, issue.1, pp.21-27, 2005.

A. Ra, T. Ap, and A. , The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer, J Clin Oncol, pp.338-340, 2006.

E. M. , H. As, and E. S. , L'aménorrhée garde-t-elle encore une valeur pronostic ? Abstract 32 ème journées de la Société Française de Sénologie et de Pathologie Mammaire, 2010.

P. Wr, D. Ag, and O. Ia, Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer : analysis of a National Cancer Institute of Cananda Clinical Trials Group Study: NCIC CTG MA5, J ClinOncol, vol.23, issue.25, pp.6002-6010, 2005.

S. Sm, J. Jh, and G. Ce, Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer, N Engl J Med, vol.362, pp.2053-65, 2010.

T. F. and B. A. De, Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer, Endoc Relat Cancer, pp.21-33, 2012.

S. Ie, D. M. , and Y. Ys, Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced ameorrhea : caution and suggested guidelines, J Clin Oncol, vol.24, pp.2444-2451, 2006.

A. Me, G. Sa, and . Es, Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer, Fertil Steril, issue.1, pp.97-154, 2012.

M. Del-re, M. A. , and S. P. , Pharmacogenetics of anti-estrogen treatment of breast cancer, Cancer Treatment Reviews, vol.38, issue.5, pp.442-450
DOI : 10.1016/j.ctrv.2011.08.003

D. Cremoux-p, D. V. , and P. M. , Le tamoxifene et les inhibiteurs d'aromatase dans le traitement des cancers du sein: aspects pharmacologiques et cliniques, Bull Cancer, issue.12, pp.91-917, 2004.

F. B. , C. Jp, and R. Ck, Endometrial cancer in Tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project ( NSABP)B-14, J Nat Cancer Inst, vol.86, pp.527-564, 1994.

G. Pj, E. M. , and P. Ki, Risk of menopause during the first year after breast cancer diagnosis, J Clin Oncol, vol.17, pp.2365-2370, 1999.

A. M. and M. S. Ginsburg, The effects of Paclitaxel, Dose Density, and Trastuzumab on Treatment-Related Amenorrhea in premenopausal women with breast cancer, pp.446-467, 2010.

D. Mastro-l, L. A. , G. S. , and P. P. , Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives, Cancer Treatment Reviews, vol.37, issue.3, pp.37-208, 2011.
DOI : 10.1016/j.ctrv.2010.07.007

K. Jg and B. F. Blamey-rw, Combined Hormone Agents Trialist' Group and the European Organization for Research and Treatment of Cancer. Combined Tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist vs LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials, J Clin Oncol, vol.19, pp.343-53, 2001.

D. Cremoux-p, Hormonothérapie des cancers du sein, Bull Cancer, vol.98, pp.1311-1319, 2011.

B. Au, Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors, Clin Cancer Res, vol.9, pp.468-472, 2003.

S. Ie, D. M. , and Y. Ys, Adjuvant Aromatase Inhibitors for early Breast Cancer After chemotherapy-induced amenorrhoea: Caution and suggested Guidelines, J of clinical Oncology, vol.24, 2006.

O. O. Pagani-o and J. A. , Which factors should be taken in account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommandations of an expert panel, Cancer Treat Rev, p.1016, 2010.

E. Kr, Aromatase Inhibitors for Ovulation and Pregnancy in polycystic Ovary Syndrome. The Annals of Pharmacotherapy, pp.1338-1346, 2009.

D. Ziegler-d, M. C. , and L. C. , Clinical use of aromatase inhibitors (AI) in premenopausal women, The Journal of Steroid Biochemistry and Molecular Biology, vol.95, issue.1-5, pp.95-121, 2005.
DOI : 10.1016/j.jsbmb.2005.04.023

P. Me and . Bulun-s, The use of Aromatase inhibitors for Ovulation Induction and Superovulation, J Clin Endocrin Metab, vol.2013, issue.985, pp.1838-1882

D. Mastro, L. A. , G. S. , and P. P. , Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives, Cancer Treatment Reviews, vol.37, issue.3, pp.208-219, 2011.
DOI : 10.1016/j.ctrv.2010.07.007

X. Hb and L. L. Liu-yj, Aromatase Inhibitor Versus Tamoxifen in Postmenopausal woman with advanced Breast cancer: a literature-based meta-analysis, Clin Breast Cancer, vol.11, issue.4, pp.246-51, 2011.

. Bergman-l, G. Beelen-ml, and . Mp, Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres'ALERT Group

A. E. Bland, C. B. , and A. Secord-a, Relationship between tamoxifen use and high risk endometrial cancer histologic types, Gynecologic Oncology, vol.112, issue.1, pp.150-154, 2009.
DOI : 10.1016/j.ygyno.2008.08.035

A. Y. , G. Du-masgenet-b, and C. P. , Echographie et imagerie pelvienne en pratique gynécologique, 5 ème edition, p.409, 2010.

. Van-calster-b, . Van-ginderachter-j, and . J. Vlasselaer, Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole, Menopause, vol.18, pp.224-229, 2010.
DOI : 10.1097/gme.0b013e3181eb9f14

H. Jb and N. St, Resumption of menses with initiaition of Letrozole after five years of amenorrhea on Tamoxifen: Caution Needed When Using Tamoxifen followed by Aromatase Inhibitors, Cancer Invest, vol.24, issue.2, pp.174-181, 2006.

B. Hj, M. E. , and P. Ah, Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons, Clin Breast Cancer, vol.7, issue.2, pp.158-161, 2006.

S. Ie, D. M. , and Y. Ys, Adjuvant Aromatase Inhibitors for early Breast Cancer After chemotherapy-induced amenorrhoea: Caution and suggested Guidelines, J Clin Oncol, issue.16, pp.24-2444, 2006.

G. J. Guerrero-a and . Folkerd, Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane, Annals of Oncology, vol.69, issue.suppl), pp.24-674, 2013.
DOI : 10.1097/gme.0b013e318204af88